Skip to main content
SpringerLink
Log in

Glaukom und trockenes Auge

Aktueller Stand und Zukunftsperspektiven

Glaucoma and dry eye

Current concepts and future perspectives

  • Leitthema
  • Published:
Der Ophthalmologe Aims and scope Submit manuscript

Zusammenfassung

Hintergrund

Der aktuelle Stand und zukünftige Perspektiven der Prävention und Therapie des trockenen Auges unter Glaukomtherapie werden diskutiert.

Methoden

Zugrunde liegen eine Literaturrecherche aus Pubmed (Schlüsselwörter: „Glaucoma“ und „dry eye“) und eigene klinische und experimentelle Daten.

Ergebnisse

Das trockene Auge ist eine der Hauptkomplikationen einer längerfristigen lokalen Glaukomtherapie. Es gibt eine direkte Korrelation der Zahl konservierter antiglaukomatöser Tropfen mit dem Oberflächenschaden.

Schlussfolgerung

Vor und während längerfristiger topischer Glaukomtherapie ist unbedingt auf das Vorliegen eines trockenen Auges zu achten und dieses adäquat zu behandeln, um langfristige Schäden und eine reduzierte Compliance des Patienten zur verhindern.

Abstract

Purpose

Current concepts and future perspectives for therapy and prevention of dry eye in glaucoma patients are described.

Methods

Own clinical and experimental findings and PubMed based literature search (keywords: glaucoma and dry eye).

Results

Ocular surface disease is the main long-term complication of glaucoma therapy. Prevention of ocular surface inflammation by preservative-free antiglaucoma eye drops and concurrent dry eye therapy are important

Conclusions

It is mandatory to treat dry eye prior to and during glaucoma therapy. Preservative-free glaucoma medication can help to ameliorate the problem.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Erb C, Gast U, Schremmer D (2008) German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye. Graefes Arch Clin Exp Ophthalmol 246(11):1593–1601

    Article  PubMed  Google Scholar 

  2. Fechtner RD, Godfrey DG, Budenz D et al (2010) Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea 29(6):618–621

    PubMed  Google Scholar 

  3. Lin Z, Liu X, Zhou T et al (2011) A mouse dry eye model induced by topical administration of benzalkonium chloride. Mol Vis 17:257–264

    PubMed Central  PubMed  Google Scholar 

  4. Zhivov A, Kraak R, Bergter H et al (2010) Influence of benzalkonium chloride on Langerhans cells in corneal epithelium and development of dry eye in healthy volunteers. Curr Eye Res 35(8):762–769

    Article  CAS  PubMed  Google Scholar 

  5. De Saint Jean M, Debbasch C, Brignole F et al (2002) Relationship between in vitro toxicity of benzalkonium chloride (BAC) and preservative-induced dry eye. Adv Exp Med Biol 506(Pt A):697–702

    Google Scholar 

  6. Pisella PJ, Pouliquen P, Baudouin C (2002) Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol 86(4):418–423

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Yenice O, Temel A, Orum O (2007) The effect of artificial tear administration on visual field testing in patients with glaucoma and dry eye. Eye 21(2):214–217

    Article  CAS  PubMed  Google Scholar 

  8. Rufer F, Erb C (2012) Influence of dry eye syndrome on glaucoma diagnostic procedures. Ophthalmologe 109(11):1082–1086

    Article  CAS  PubMed  Google Scholar 

  9. Herrero-Vanrell R, Peral A (2007) International Dry Eye Workshop (DEWS). Update of the disease. Arch Soc Esp Oftalmol 82(12):733–734

    CAS  PubMed  Google Scholar 

  10. Gomes JA, Rocha EM, Freitas D, Sullivan DA (2011) Workshop on meibomian gland dysfunction. Arq Bras Oftalmol 74(3):157–160

    Article  PubMed  Google Scholar 

  11. Ta CN, Shine WE, McCulley JP et al (2003) Effects of minocycline on the ocular flora of patients with acne rosacea or seborrheic blepharitis. Cornea 22(6):545–548

    Article  PubMed  Google Scholar 

  12. Pult H, Riede-Pult B (2013) Comparison of subjective grading and objective assessment in meibography. Cont Lens Anterior Eye 36(1):22–27

    Article  PubMed  Google Scholar 

  13. Pult H, Riede-Pult BH (2012) Non-contact meibography: keep it simple but effective. Cont Lens Anterior Eye 35(2):77–80

    Article  CAS  PubMed  Google Scholar 

  14. Na KS, Kim MS (2012) Allogeneic serum eye drops for the treatment of dry eye patients with chronic graft-versus-host disease. J Ocul Pharmacol Ther 28(5):479–483

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Chiang CC, Lin JM, Chen WL, Tsai YY (2007) Allogeneic serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease. Cornea 26(7):861–863

    Article  PubMed  Google Scholar 

  16. Steven P, Cursiefen C (2012) Anti-inflammatory treatment in dry eye disease. Klin Monatsbl Augenheilkd 229(5):500–505

    Article  CAS  PubMed  Google Scholar 

  17. Bock F, Maruyama K, Regenfuss B et al (2013) Novel anti(lymph)angiogenic treatment strategies for corneal and ocular surface diseases. Prog Retin Eye Res 34:89–124

    Article  CAS  PubMed  Google Scholar 

  18. Sheppard JD, Scoper SV, Samudre S (2011) Topical loteprednol pretreatment reduces cyclosporine stinging in chronic dry eye disease. J Ocul Pharmacol Ther 27(1):23–27

    Article  CAS  PubMed  Google Scholar 

  19. Schrell C, Cursiefen C, Kruse F, Jacobi C (2012) Topical Cyclosporine A 0.05 % in the treatment of keratoconjunctivitis sicca. Klin Monatsbl Augenheilkd 229(5):548–553

    Article  CAS  PubMed  Google Scholar 

  20. Kruse FE, Cursiefen C (2008) Surgery of the cornea: corneal, limbal stem cell and amniotic membrane transplantation. Dev Ophthalmol 41:159–170

    Article  CAS  PubMed  Google Scholar 

  21. Bock F, Onderka J, Dietrich T et al (2007) Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 48:2545–2552

    Article  PubMed  Google Scholar 

  22. Cursiefen C, Rummelt C, Beckman MW, Kruse FE (2006) Amniotic membrane-covered bio-onlays for treatment of ocular surface disease. Br J Ophthalmol 91:841–842

    Article  Google Scholar 

  23. Jacobi C, Jacobi A, Kruse FE, Cursiefen C (2011) Tear film osmolarity measurements in dry eye disease using electrical impedance technology. Cornea 30(12):1289–1292

    Article  PubMed  Google Scholar 

  24. Bachmann B, Jacobi C, Cursiefen C (2011) Inflammation of the eye in systemic inflammatory disorders: keratitis. Klin Monatsbl Augenheilkd 228:413–418

    Article  CAS  PubMed  Google Scholar 

  25. Jacobi C, Bellios N, Jacobi A et al (2011) Screening questionnaire for documentation of medical history and diagnostic findings in dry eye disease. Klin Monatsbl Augenheilkd 228:226–233

    Article  CAS  PubMed  Google Scholar 

  26. Jacobi C, Dietrich T, Cursiefen C, Kruse FE (2006) The dry eye. Current concepts on classification, diagnostics, and pathogenesis. Ophthalmologe 103:9–17

    Article  CAS  PubMed  Google Scholar 

  27. Cursiefen C, Jacobi C, Dietrich T, Kruse FE (2006) Current treatment for dry eye syndrome. Ophthalmologe 103:18–24

    Article  CAS  PubMed  Google Scholar 

Download references

Einhaltung ethischer Richtlinien

Interessenkonflikt. P. Steven hat Honorare, Reisemittel und/oder Forschungsförderungen von folgenden Firmen erhalten: Allergan, Alcon, Bausch+Lomb, Chefaro, Novaliq, MSD, Oculus, Haag-Streit Surgical. C. Cursiefen: Consultant Allergan, Gene Signal, Novaliq. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren. Alle Patienten, die über Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts zu identifizieren sind, haben hierzu ihre schriftliche Einwilligung gegeben. Im Falle von nicht mündigen Patienten liegt die Einwilligung eines Erziehungsberechtigen oder des gesetzlich bestellten Betreuers vor.

Author information

Authors and Affiliations

  1. Universitätsaugenklinik Köln, Universität zu Köln, Kerpener Str. 62, 50924, Köln, Deutschland

    P. Steven &  C. Cursiefen

Authors
  1. P. Steven
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Cursiefen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Cursiefen.

Additional information

__Förderung____

DFG (Cu 47/4-1), DFG (SFB 634/B10), DFG (STE 1928/2-1), DFG (HE 6743/2-1), GEROK Programm Universität Köln (LMH), Bayer Graduate Program Pharmakologie (CC), Köln Fortune, Sicca-Forschungsförderung des BVA, Ruth und Helmut Lingen Stiftung Köln.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Steven, P., Cursiefen, C. Glaukom und trockenes Auge. Ophthalmologe 110, 1155–1159 (2013). https://doi.org/10.1007/s00347-012-2675-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00347-012-2675-z

Schlüsselwörter

Keywords

Search

Navigation